美国新墨西哥州HPV与细胞学联合筛查的 uptake 评估
该研究基于新墨西哥州2008至2019年681,440名21-64岁女性的1,704,055次宫颈筛查检测,评估HPV与细胞学联合筛查的 uptake。30-64岁女性联合筛查比例从2008年5.6%升至2019年84.3%,2013-2015年增幅最大,反映新临床指南的引入与采纳;年轻女性联合筛查也有增加,但当前不推荐。
要点
- 30-64岁女性联合筛查比例从2008年5.6%升至2019年84.3%。
- 2013-2015年增幅最大,反映新临床指南的引入与采纳。
- 年轻女性联合筛查也有增加,但当前不推荐。
核心结论
- 联合筛查在30-64岁女性中已确立,但年轻女性也有较小幅度的增加,尽管当前不推荐。
研究设计与样本
- 基于注册的研究,纳入新墨西哥州2008至2019年21-64岁女性的所有筛查细胞学和HPV检测,共1,704,055次检测来自681,440名女性,重点关注细胞学阴性检测以区分联合筛查与反射性HPV检测。
主要发现
- 30-64岁女性联合筛查比例从2008年5.6%升至2019年84.3%。
- HPV检测方法从近乎 exclusively 使用 Hybrid Capture II 信号放大检测转为使用 target amplified HPV 检测。
- 2013至2015年联合筛查增幅最大。
- 年轻女性联合筛查也有增加。
临床怎么用
- 联合筛查在30-64岁女性中已广泛采用,临床应关注其在常规人群中对宫颈疾病结局及阴道镜和活检数量的影响,尤其在年轻女性中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Human papillomavirus (HPV) testing for cervical screening has been shown to increase the yield of precancerous disease and reduce the incidence of cervical cancer more than cytology alone. Here we document the state-wide uptake of co-testing with HPV and cytology in women aged 30-64 years as recommended by national and international bodies. METHODS: Registry-based study of all screening cytology and HPV tests in New Mexico from 2008 to 2019 among women aged 21-64 years, with a focus on cytology negative tests to distinguish co-testing from reflex HPV testing to triage equivocal or mildly abnormal cytology. RESULTS: A total of 1,704,055 cervical screening tests from 681,440 women aged 21-64 years in the state of New Mexico were identified. The proportion of screening tests which were co-tests rose from 5.6% in 2008 to 84.3% in 2019 among women aged 30-64 years with a marked change from the near exclusive use of the Hybrid Capture II HPV test, (a signal amplified test method) to the use of target amplified HPV tests. The largest increases were seen between 2013 and 2015, reflecting the introduction and adoption of new clinical guidelines. Increases in co-testing were also seen in younger women. CONCLUSIONS: Co-testing is now well established in women aged 30-64 years, but smaller increases have also been seen at younger ages, although this is not currently recommended. The impact of co-testing on cervical disease outcomes and number of colposcopies and biopsies in routine population settings remain important, especially in young women.
引用
- Cuzick J, Du R, Adcock R, et al. Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States. Gynecol Oncol. 2021. PMID: 34253387. doi:10.1016/j.ygyno.2021.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。